Novartis Toekomstige groei

Future criteriumcontroles 2/6

Novartis zal naar verwachting groeien in winst en omzet met respectievelijk 7% en 2.2% per jaar. De winst per aandeel zal naar verwachting groeien met 9.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 37% zijn.

Belangrijke informatie

7.0%

Groei van de winst

9.1%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	11.9%
Inkomstengroei	2.2%
Toekomstig rendement op eigen vermogen	37.0%
Dekking van analisten	Good
Laatst bijgewerkt	23 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

SWX:NOVN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	53,242	13,195	16,857	19,530	14
12/31/2025	52,663	12,472	16,067	18,507	17
12/31/2024	50,374	10,989	14,775	16,979	17
9/30/2024	49,940	11,761	12,552	15,973	N/A
6/30/2024	48,860	10,083	13,560	15,065	N/A
3/31/2024	47,733	9,107	12,071	13,766	N/A
12/31/2023	46,660	8,568	13,660	14,458	N/A
9/30/2023	45,850	7,245	15,507	16,022	N/A
6/30/2023	44,541	7,062	13,241	15,365	N/A
3/31/2023	41,694	5,976	14,009	15,544	N/A
12/31/2022	43,461	6,049	12,167	14,236	N/A
9/30/2022	46,017	21,042	11,545	14,009	N/A
6/30/2022	48,601	22,472	11,714	14,213	N/A
3/31/2022	52,997	24,184	12,349	14,590	N/A
12/31/2021	43,974	22,908	13,201	15,071	N/A
9/30/2021	52,385	9,807	13,015	15,192	N/A
6/30/2021	51,556	8,984	11,222	13,423	N/A
3/31/2021	49,884	7,955	10,699	13,252	N/A
12/31/2020	49,898	8,072	11,445	13,650	N/A
9/30/2020	49,584	7,103	11,743	13,185	N/A
6/30/2020	49,528	7,210	13,255	14,591	N/A
3/31/2020	49,930	7,451	13,077	14,240	N/A
12/31/2019	48,677	7,142	12,341	13,625	N/A
9/30/2019	47,858	7,238	12,122	13,851	N/A
6/30/2019	46,762	7,077	11,477	13,339	N/A
3/31/2019	46,391	12,697	11,778	13,671	N/A
12/31/2018	46,099	12,797	12,447	14,272	N/A
9/30/2018	47,366	13,552	11,748	13,914	N/A
6/30/2018	48,672	13,752	N/A	13,450	N/A
3/31/2018	49,513	8,004	N/A	13,090	N/A
12/31/2017	43,404	7,499	N/A	12,621	N/A
9/30/2017	49,527	6,684	N/A	12,804	N/A
6/30/2017	49,176	6,543	N/A	12,449	N/A
3/31/2017	49,361	6,367	N/A	11,978	N/A
12/31/2016	49,386	6,712	N/A	11,475	N/A
9/30/2016	49,606	6,807	N/A	12,041	N/A
6/30/2016	49,750	6,672	N/A	11,936	N/A
3/31/2016	49,967	6,722	N/A	11,735	N/A
12/31/2015	50,387	7,017	N/A	11,897	N/A
9/30/2015	50,635	8,417	N/A	12,945	N/A
6/30/2015	51,450	9,697	N/A	13,830	N/A
3/31/2015	52,503	10,536	N/A	14,260	N/A
12/31/2014	53,634	10,657	N/A	13,897	N/A
9/30/2014	53,908	10,191	N/A	13,142	N/A
6/30/2014	53,514	9,233	N/A	13,510	N/A
3/31/2014	52,845	9,095	N/A	12,687	N/A
12/31/2013	52,716	9,192	N/A	13,174	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei NOVN ( 7% per jaar) ligt boven de spaarquote ( 0.3% ).

Winst versus markt: De winst van NOVN ( 7% per jaar) zal naar verwachting langzamer groeien dan de markt Swiss ( 11.4% per jaar).

Hoge groeiwinsten: De winst van NOVN zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van NOVN ( 2.2% per jaar) zal naar verwachting langzamer groeien dan de markt Swiss ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van NOVN ( 2.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen NOVN zal naar verwachting over 3 jaar hoog zijn ( 37 %)

Novartis Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis AG Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 13%

Recent updates

Novartis AG (SWX:NOVN) acquired Kate Therapeutics, Inc. in a transaction valued at $1.1 billion.

New minor risk - Earnings quality

We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Novartis AG's (VTX:NOVN) Price In Tune With Earnings

Upcoming dividend of CHF3.30 per share

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Final dividend of CHF3.30 announced

New minor risk - Earnings quality

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Is There An Opportunity With Novartis AG's (VTX:NOVN) 47% Undervaluation?

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Consensus EPS estimates increase by 13%

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven